Replies to post #84557 on Biotech Values

[stockbettor]

MNTA: >>No, this announcement does not change anything in my valuation analysis.<<

But might it not change the overall probablity for the launch of an authorized generic? In one of your late 2008 posts, you assigned a > 35% chance to the launch of an AG in response to zipjet's 20% assignment. I had not focused on sanofi' in-house generics operation until yesterday's press release, but I see that sanofi did complete its acquisition of Zentiva, a branded generics firm, earlier this year. In its 2008 review, sanofi announced that it would expand its branded generics program. Given this, my guess on an AG is > 50%. Still, single AG competition is not a bad outcome and might have the effect of discouraging additional competitors from engaging in the difficult task of producing a lovenox copy.